

## Notice of References Cited

	-		
Application/Control No.	THE STATE OF THE S	Applicant(s)/F	Under
09/954,953	4 1/	Reexamination MINOTTI ET	
Examiner		Art Unit	D 4 . 64
Devesh Khare		1623	Page 1 of 1

## **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-6,340,701B1	01-2002	Chari et al.	514/449
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	H	US-			
	1	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	Р					
	Q					
	R					
	S					
	T					

## **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Sparano, "Doxorubicin/Taxane combinations: Cardiac toxicity and pharmacokinetics." Seminars in Oncology, Vol.26, No.3, Suppl.9 (June 1999), pages 14-19.
	٧,	Gianni et al.," Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel patients with breast cancer." Journal of clinical oncology, vol.15, no.5, (May 1997), pages 1906-1915.
	w'	Zoli et al." In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers." Breast Cancer Research and Treatment ,34, 1995, pages 63-69.
	х	Wahl et al. "Selective tumor sensitization to taxanes with the mab-drug conjugate CBR96-doxorubicin." Abstract: Int. J. Cancer vol. 4, (15 Aug. 2001), pages 590-600.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.